Abstracts Archive - Page 1641 of 2607 - ACR Meeting Abstracts

Abstract Number: 623 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 624 • 2016 ACR/ARHP Annual Meeting
Association Between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima³ and Naoki Ishiguro⁴, ¹orthopedic surgery, Sakashita Hospital, Nakatsugawa, Japan, ²Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: In general, the concomitant use of methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDS) plays an important role in treating bio-naïve patients with rheumatoid…
Abstract Number: 625 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
John Tesser¹, Shelly Kafka², Raphael J. DeHoratius³, Stephen Xu⁴, Kehzen L. Tang⁴, Elizabeth C. Hsia⁵ and Anthony Turkiewicz⁶, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Rheumatology Associates, Birmingham, AL
Background/Purpose: There is a paucity of data on the use of anti-TNF therapy in patients >65 years. In this sub-analysis of GO-FURTHER, we compare the…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
L Tweehuysen¹, B.J.F. van den Bemt², I.L. van Ingen³, A.J.L. de Jong⁴, W.H. van der Laan⁵, F.H.J. van den Hoogen⁵ and A.A. den Broeder⁵, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, ⁴Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Klaus Krüger¹, GR Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius, München, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumazentrum, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…
Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Michael Kruse Meyer^1,2, Marlene Andersen^1,3, Troels Vindbæk Stausbo⁴, Tue Bjerg Bennike^4,5, Grethe Neumann Andersen^1,6 and Allan Stensballe^3,4, ¹Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ²Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ⁵Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, ⁶Center for Clinical Science, Aalborg University, Hjørring, Denmark
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
Abstract Number: 631 • 2016 ACR/ARHP Annual Meeting
Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Alfredomaria Lurati¹, Magda Scarpellini², Katia Angela re³, Mariagrazia Marrazza³, Daniela Mazzocchi³ and Antonella Laria⁴, ¹Fornaroli Hospital Rheumatology Unit Magenta Italy, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy, ³Fornaroli Hospital, Rheumatology Unit, MAgenta, Italy, ⁴Fornaroli Hospital, Rheumatology Unit, Magenta, Italy
Biologic free remission rate with etanercept in rheumatoid arthritis: a potential role of gender A.M. Lurati and A. Laria, D. Mazzocchi, K.A. Re, M. Marrazza,…
Abstract Number: 632 • 2016 ACR/ARHP Annual Meeting
Comparative Improvement in Health-Related Quality of Life for RA Patients Between TNF-α Inhibitors, Other Biologics, and Tofacitinib: Results from a US-Wide Observational Study
Miriam G. Cisternas¹ and Kaleb Michaud^2,3, ¹MGC Data Services, Carlsbad, CA, ²University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: We compared changes from baseline for 8 health-related quality of life (HR-QOL) outcomes over two years for patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 633 • 2016 ACR/ARHP Annual Meeting
High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
L. Tweehuysen¹, K. Schraa², M.G. Netea³, F.H.J. van den Hoogen^4,5, L.A.B. Joosten³ and A.A. den Broeder⁴, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Internal Medicine, Radboudumc, Nijmegen, Netherlands, ³Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁴Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Better prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualized treatment. Clinical data suggest that the response of…
Abstract Number: 634 • 2016 ACR/ARHP Annual Meeting
Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment
Daniela Di Giuseppe¹, Thomas Frisell², Sofia Ernestam^3,4, Helena Forsblad D’Elia⁵, E. Lindqvist⁶, Ulf Lindström⁷, Johan Askling^8,9 and ARTIS, ¹Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden, ⁴Clinical Epidemiology unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology, Lund University, Lund, Sweden, ⁷Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: In March 2015 the first infliximab biosimilars CT-P13 (Remsima™; Inflectra™), entered the Swedish market. The aim of this study was to evaluate the uptake…
Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting
Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Jaime Calvo-Alen¹, Indalecio Monteagudo², Georgina Salvador Alarcón³, Enrique Raya Álvarez⁴, Loreto Carmona⁵, Luis Cea-Calvo⁶ and Carlos Marras Fernandez-Cid⁷, ¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ²Rheumatology Unit, HGU Gregorio Marañón, Madrid, Madrid, Spain, ³Rheumatology, HU Mutua de Terrassa, Barcelona, Terrassa, Spain, ⁴Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ⁵Instituto de Salud Musculoesquelética, Madrid, Spain, ⁶Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain, ⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain
Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…
Abstract Number: 636 • 2016 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Iñigo Gorostiza¹, Eduardo Úcar Angulo², Catalina Gómez Arango², Clara Eugenia Perez³, Juan Ramon De Dios⁴, Belen Alvarez⁴, Ana Ruibal Escribano^4,5, Claudia Stoye⁴, Margarida Vasques⁴, Joaquin Belzunegui Otano⁶, Antonio Escobar⁷, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Research Department, Hospital Universitario de Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁶Donostia University Hospital, San Sebastian, Spain, ⁷Unidad de Investigación, Red de Investigación en Servicios de Salud en enfermedades crónicas (REDISSEC), Hospital Universitario de Basurto, Bilbao, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain
Background/Purpose: Adalimumab (ADL) dose tapering based on clinical assessment is a usual practice especially in patients who have achieved clinical remission. The primary aim of…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].